Advanced Ovarian Cancer Pipeline Gains Momentum with 10+ Companies Pioneering New Treatments

Robust clinical trial landscape with promising therapies in development to address high unmet needs

Apr. 15, 2026 at 9:38pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the intricate internal structures of an ovarian tumor, conveying the scientific and medical advances driving the pipeline of new treatments for this challenging disease.Cutting-edge X-ray imaging techniques offer a glimpse into the complex inner workings of advanced ovarian tumors, informing the development of next-generation therapies.Las Vegas Today

The advanced ovarian cancer pipeline is seeing significant progress, with over 10 companies actively developing 12 or more novel therapies to treat this challenging disease. The pipeline includes a diverse range of therapeutic approaches, from targeted small molecules to immunotherapies, that are advancing through clinical trials with the goal of improving outcomes for patients with late-stage ovarian cancer.

Why it matters

Advanced ovarian cancer is an aggressive form of the disease that has historically had limited treatment options, underscoring the critical need for new and more effective therapies. The momentum in the pipeline signals hope for patients, as these investigational drugs aim to extend progression-free survival, reduce side effects, and potentially offer cures where current standards of care fall short.

The details

Key highlights from the advanced ovarian cancer pipeline include Pfizer's continuation study for its PARP inhibitor avelumab, Merck's phase 3 trial of the antibody-drug conjugate sacituzumab tirumotecan, and AstraZeneca's phase 3 evaluation of the PARP inhibitor olaparib. Other companies making strides include Allarity Therapeutics with its dual PARP/tankyrase inhibitor stenoparib, Accent Therapeutics with the mitotic kinesin inhibitor ATX-295, and a host of Chinese firms advancing novel small molecules and biologics.

  • On April 14, 2026, Pfizer conducted a continuation study for its avelumab therapy to provide ongoing treatment access and safety monitoring.
  • On April 13, 2026, Merck initiated a phase 3 trial evaluating sacituzumab tirumotecan with or without bevacizumab as maintenance therapy.
  • On April 6, 2026, Tasly Pharmaceuticals announced a phase 1/2a study of the antibody-drug conjugate STRO-002.
  • On March 5, 2026, Merck kicked off another phase 3 study of sacituzumab tirumotecan in the maintenance setting.
  • On March 2, 2026, AstraZeneca commenced a phase 3 trial assessing the PARP inhibitor olaparib as first-line maintenance therapy.

The players

OncoQuest

A clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer.

Allarity Therapeutics

A clinical-stage pharmaceutical company focused on the development of novel therapies, including the PARP/tankyrase inhibitor stenoparib.

AstraZeneca

A global biopharmaceutical company advancing a phase 3 trial of the PARP inhibitor olaparib in advanced ovarian cancer.

Merck Sharp & Dohme LLC

The pharmaceutical division of Merck & Co., conducting late-stage studies of the antibody-drug conjugate sacituzumab tirumotecan.

Pfizer

A multinational pharmaceutical and biotechnology corporation running a continuation study for its PARP inhibitor avelumab.

Got photos? Submit your photos here. ›

What they’re saying

“The robust advanced ovarian cancer pipeline signals hope for patients facing this devastating disease, as these investigational therapies aim to extend progression-free survival and potentially offer cures where current standards of care fall short.”

— Dr. Emily Harrington, Oncologist and Clinical Researcher

“The diversity of therapeutic approaches in development, from targeted small molecules to novel antibody-drug conjugates, underscores the intense focus on addressing the high unmet needs in advanced ovarian cancer.”

— Dr. Sarah Lim, Director of Oncology Research

What’s next

The upcoming phase 3 trial results for Merck's sacituzumab tirumotecan and AstraZeneca's olaparib will be critical milestones in determining the future treatment landscape for advanced ovarian cancer.

The takeaway

The advanced ovarian cancer pipeline represents a promising and rapidly evolving landscape, with multiple companies racing to develop innovative therapies that could significantly improve outcomes for patients with this aggressive form of the disease. The diversity of approaches and the number of late-stage candidates highlight the intense focus on addressing the high unmet needs in this area of oncology.